Dr. Jonasch on Sequencing Challenges in RCC

Eric Jonasch, MD
Published: Tuesday, Dec 05, 2017



Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses sequencing challenges facing patients with renal cell carcinoma (RCC).

A sequencing challenge in the second-line setting is whether to start with a checkpoint antibody, such as nivolumab (Opdivo) or a multikianse inhibitor like cabozantinib (Cabometyx).

Nivolumab is well tolerated for the majority of patients who receive it. There is a subset of individuals who benefit from it. At this point in time, there are not good predictors of which agent should be given to which patient.
 
SELECTED
LANGUAGE


Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses sequencing challenges facing patients with renal cell carcinoma (RCC).

A sequencing challenge in the second-line setting is whether to start with a checkpoint antibody, such as nivolumab (Opdivo) or a multikianse inhibitor like cabozantinib (Cabometyx).

Nivolumab is well tolerated for the majority of patients who receive it. There is a subset of individuals who benefit from it. At this point in time, there are not good predictors of which agent should be given to which patient.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x